FDA Inspection 1254733 — Haimen Pharma Co., Ltd.

Haimen Pharma Co., Ltd. — FEI 3011266110

The FDA completed an inspection of Haimen Pharma Co., Ltd. on August 25, 2023 in Nantong. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
August 25, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Nantong (China)

Additional Details

Mutual Recognition Agreement (MRA)